Pulmatrix Inc (PULM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.39+2.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Operating cash flow improves to at least -$1.07M by 2026-Q1: metric not reported.
Pulmatrix is improving cash flow, cutting losses from -$3.68M to -$1.07M. The company plans to have enough cash to operate into early 2027. It completed a merger to expand its capabilities. These steps could help it grow and survive.
Pulmatrix is still losing money and depends on raising cash. The merger progress is uncertain. If it cannot improve cash flow or grow, it may run out of money.
The price is about 44% below our fair value near $3. Analysts expect 5% revenue growth. Our view is cautious due to losses and uncertain growth.
Breaks if: operating cash flow worse than -1.07 million USD by 2026-Q1
Breaks if: cash runway falls short of 2027-Q1
Breaks if: merger not completed or integration fails by 2026-Q2
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, which raises concerns about its stability in the near term.
The market seems to have priced in a low level of fragility, indicating that expectations are somewhat justified. PULM is viewed as cheap compared to its peers, but there is a notable expectations gap that suggests the market anticipates further challenges.
Fundamentals are likely to remain under pressure due to recent weak performance and high risk. Management is focused on completing a merger and enhancing capital allocation, which may help extend the cash runway but does not guarantee immediate improvements.
The long-term thesis hinges on the successful completion of the merger with Eos SENOLYTIX and the ability to maintain operational efficiency. Additionally, external factors such as sector performance and economic conditions will play a crucial role in determining PULM's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Finalize merger agreement and integration with Eos SENOLYTIX to expand company capabilities and pipeline.
In the next 1 to 3 years, PULM's outlook will depend heavily on management execution and broader market conditions. Not investment advice.